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Dear Friends and Colleagues:

LETTER TK

The year 2008 will be remembered for a number of things — among them an economic crisis that tested the foundation of the global financial system and, despite receiving less public attention, the HIV pandemic continued to
overwhelm our best efforts to control it.
Treatment advances have been revolutionary, but treatment alone will not resolve the HIV/AIDS crisis. The public
health community has responded by focusing its attention and scientific ingenuity on HIV prevention, because
it offers the best long-term solution to control the pandemic. We have also seen a new consensus on the need to
prioritize the development of microbicides designed to protect women from HIV. From the outset, IPM has focused
on advancing the most promising microbicides that are based on highly potent antiretrovirals (ARVs). In 2008, IPM
added two new ARV compounds to its portfolio. We also intensified work on developing microbicides based on
combinations of drugs.
Most important, we moved forward IPM’s most clinically advanced microbicide candidate, dapivirine, in several
forms — including gels, films and a novel vaginal ring that could offer longer-lasting protection. Understanding the
types of products women would really want and use is essential, and IPM is learning more about women’s preferences in ongoing acceptability studies.
To prepare for upcoming large-scale clinical trials, IPM greatly expanded its clinical programme and partnerships
with local communities. Long after our studies are completed, our investments in facilities and training programmes will offer benefits to communities — from education to training to infrastructure. Looking even further
ahead, we began devising manufacturing and access strategies so that once microbicides are proven safe and effective, they can quickly reach women who need them.
We are mindful of the ongoing global economic crisis and are enormously grateful for our donors, who demonstrate a strong commitment to HIV prevention and to giving women tools to protect themselves from this virus. In
2008, IPM received new and continued support from 14 donors — our broadest base of support ever. We are heartened by this confidence in IPM and our scientific strategy, especially given the ongoing support needed to conduct
trials and eventually put a product into women’s hands. In this economic climate, the microbicide field can expect
ever-greater scrutiny, and IPM will continue to be a careful steward of our donors’ support.
We are also grateful for the work of our Board of Directors, our scientific advisors and our dedicated staff. We
welcome the leadership of our incoming Board Chair, Dr. Alex G. Coutinho, Executive Director of the Infectious
Diseases Institute at Makerere University in Uganda. IPM also has many partners around the world, from our colleagues in the private sector to government and civil society and to the women who volunteer for IPM studies — the
true leaders of the HIV prevention effort. Our critical advances this year would not have been possible without all of
this extraordinary commitment.
In this report, we are pleased to highlight IPM’s progress in developing microbicides and invite you to join us in
sustaining this momentum for the year ahead.
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IPM employees at the Clinical Trial Material Facility in
Bethlehem, Pennsylvania, USA, where vaginal rings and
gels are produced and packaged for use in
IPM clinical trials.
(Andrew Loxley, Felt Photography)

As IPM prepares for large-scale
trials of promising drug candidates
and helps build capacity at local research
centres in Africa, it is fulfilling its mandate to support the development of products that would protect
the health of millions of people and contribute to global
development. Building and renovating local research facilities, raising HIV awareness, training research centre staff, and
supporting linkages among research centres and public health
clinics — all conducted with broad community support — are
designed to benefit participating communities. These efforts are moving
ahead today as IPM and its global partners make progress
in preventing HIV tomorrow.
Bryana Williams, Production Technician,
takes a peek at the gel product manufactured at IPM’s CTM Facility.
(Andrew Loxley, Felt Photography)

Progress on the path to HIV prevention
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The pressing need for prevention

Progress in the face of challenge

Revolutionary advances in treating AIDS must be complemented

The development of any new drug is time-consuming, expensive

with progress in HIV prevention to defeat the epidemic. Ac-

and scientifically challenging. Temporary setbacks are an expected

cording to the UN, for every two people who receive treatment,

part of the process. To expedite development of promising tech-

five more people are newly infected, and only one-third the
number of people who need AIDS treatment receives it.

nologies like microbicides, IPM follows the product
development partnership (PDP) model, which

When new infections occur in women — and approxi-

synchronizes efforts across the public and private

mately 60 percent of those infected

sectors. IPM collaborates with numerous part-

with HIV in sub-Saharan Africa

ners — governments, foundations, universities,

are women — entire families

researchers, pharmaceutical companies, policy-

and communities suffer. In

makers, advocates and the women living in the

developing countries, the local
food supply (mostly

communities where trials are taking place. Those
coordinated efforts have brought IPM to the

produced by women) often

threshold of large-scale clinical testing of

shrinks. Children, espe-

promising ARV-based microbicide candidates.

cially young girls, are called

To ensure that microbicides, once developed,

upon to care for the family,

are readily available to women who need them

even if that means leaving
school or wage-paying work.

most, IPM and its partners are also actively preparing the way for future regulatory approval, and

The need for microbicides

manufacturing and distribution of a microbi-

is as great now as ever, as HIV

cide product when it is proven to be safe

continues to threaten individu-

and effective.

als, families, communities and the
world we share.

Geoff Oliver Bugbee

ARVs
From proven treatment to prevention

IPM has been instrumental in advancing research and

specifically target HIV and work by protecting host cells from

development of next generation microbicide compounds

virus attack. The most advanced ARV-based compounds,

based on antiretrovirals (ARVs), the same drugs used suc-

used alone or in combination with other ARVs, are now mov-

cessfully to treat HIV/AIDS in millions of people. ARVs offer

ing forward through the microbicide development pipeline in

important possibilities for HIV prevention because they

a variety of formulations.
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Taking Stock: IPM Evaluation
Geoff Oliver Bugbee

In 2008, public and private donors to IPM conducted an

The evaluation concurs with this

independent evaluation of IPM’s effectiveness, efficiency,

vital interpretation of IPM’s role.”

sustainability and impact. After thoroughly examining IPM’s
work from 2003 to 2007 — from its strategic direction to its

While much difficult work still lies ahead, the study con-

operating systems and myriad aspects of its drug develop-

cludes that IPM has “contributed significantly toward the

ment programme in between — the evaluation concluded

goal of developing safe and effective microbicides, and peers

that “IPM has recorded impressive accomplishments and has

recognize its accomplishments as ones which would not

positioned itself well to reach its goals of developing safe

otherwise have been achieved.”

and effective microbicides to prevent HIV.”

The five-year evaluation also included several recommendations.

The study particularly

IPM already has made progress

looked at how IPM’s mis-

in a number of these areas, in-

sion has evolved since it

cluding developing a formalized

was founded in 2002, as

product/formulation management

it moved “into a product

process, strengthening IPM’s

developer, addressing

clinical team and updating its

the gap in the field at the

strategic plan (read the full evalu-

time for greater focus on

ation report and IPM’s

antiretroviral-based

management response at

microbicides. This evolu-

www.ipm-microbicides.org).

tion was appropriate …

Richard Lord

“

HIV/AIDS has had a devastating effect on my community. The loss of life and productivity has led to poverty.
The ever-increasing cases of child-run households and stigma have also become a major concern. The training I am receiving to work at the research centre will help me address those concerns. Stigma, for instance,
has led to poor access to treatment, and different organizations in my community are working collaboratively
to improve this situation. I have learned how to reach out to my community and effectively mobilize its support. My training will enable me to respond to the future needs of my community and my country.

— Kwezi Shumi, Community Liaison Officer, Be Part Yoluntu Centre, Mbekweni, South Africa

”
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“

I’ve seen many changes in the community where an IPM study is going to take place. With the building
in the area, community members see this as ‘someone’ coming in to do something in their community.
The clinic that has been built for the IPM study has brought staff who are creating stronger relationships
with the government health workers. The IPM community educator assists in HIV prevention talks at the
government clinics and in the larger community. The clinic staff also help in providing family planning and
antenatal services while waiting for the implementation of the study.

”

— Linly Seyama, Community Liaison Officer, Johns Hopkins Research Project, Malawi College of Medicine,
Blantyre, Malawi

A study nurse demonstrates a screening exam at
Reproductive Health and HIV Research Unit in
Edendale, South Africa. (Geoff Oliver Bugbee)
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eventual product access. IPM outreach activities took on special

IPM is a leader
in global efforts
to identify
new microbicide comPreparing
communities
for safety
and
importance this past year as effectiveness trials approach. IPM
efficacy trials.

continued
to receive strong and sustained political and financial
pounds that safely and effectively combat HIV, and
to focus

With large-scale Phase III efficacy trials of IPM’s most advanced

support, essential for ongoing product development efforts.

resources on the most promising candidates. Working with

candidates, dapivirine ring and gel, scheduled to begin in 2011,
IPM is making preparations in the communities, a significant

partners in academia and industry, IPM coordinates diverse

undertaking. Clinical trials rely on coordination with gov-

ernments
and communities
where they takeefforts
place — and
wheredirectly
worldwide
drug development

funds

HIV/AIDS has been most destructive — as well as on tens of
thousands
volunteers and
the development
of essential
local
manyofprojects.
By closely
evaluating
candidates

and

infrastructure and skills. This past year, IPM and its partners

into account
theofbroader
pipeline
weretaking
able to increase
the number
participating
researchof

the entire

centres and further develop the infrastructure and capacity of

microbicide field, IPM makes choices that opti-

existing centres.

mize resources and scientific strategies.

Other advances, from development to
launch.
At the same time IPM’s most advanced candidates are moving
A member of the
community
forward, two new candidates entered the microbicide
R&D
pipe- mobilizers group,

which educates community members about clinical

trials, works
Projet Ubuzima, an
line, potentially increasing the number of options
thatwith
eventu-

IPM-sponsored research centre, in Kigali,

ally will be available to women for HIV prevention.
IPM and
itsBugbee)
Rwanda. (Geoff
Oliver
partners also continued to support efforts to strengthen regulatory approval pathways and identify full-scale manufacturing,
distribution and product launch strategies, preparing the way for
Richard Lord

The path to promising microbicide candidates
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Ongoing research for new options
Even after the first safe and effective microbicide is developed,
work will continue to increase potency and offer a variety of
product options. The reasons are many: as with any drug, a
specific microbicide product may work better in some women
than in others, and a particular method of using a microbicide
may appeal to some people more than others.

Taking ARVs forward

A woman in Mombasa, Kenya, watches a performance about HIV prevention by
the drama group House of Courage. (Geoff Oliver Bugbee)

New compounds, important progress
This past year, IPM and its partners made significant additions to

From its beginning, IPM has concentrated its efforts on what

the pipeline with two new compounds that interrupt HIV infec-

has become one of the most promising strategies in the field:

tion early in the process. IPM entered into a royalty-free licensing

ARV-based compounds. IPM and its partners are investigating

agreement with Pfizer for a new ARV compound called maraviroc.

these next generation microbicides, to be administered singly
or in combination with other drugs. IPM is also developing a
range of innovative topical dosage forms, including daily use
gels, films, gel capsules and combination vaginal tablets as well
as longer-acting vaginal rings that would be replaced monthly.
Currently, IPM has royalty-free licensing agreements with five
pharmaceutical partners for eight microbicide compounds.

Already approved by the US Food and Drug Administration
(FDA) and fully licensed for use as an HIV therapy, maraviroc
has established safety and efficacy data that may speed its development as a microbicide. Known as a CCR5 blocker, maraviroc
prevents HIV from gaining entry to the host cell.
IPM also entered into another royalty-free agreement with Merck
for L’664, an ARV compound known as a fusion inhibitor that
prevents HIV from attaching to the host cell.

Prioritizing resources:

Pipeline Growth & Management

Which compounds deserve to be explored further? Which com-

Regularly applied to compounds in the pipeline as new data

pounds no longer merit study? This past year, IPM formalized

become available, this decision-making process will continue to

an algorithm for evaluating proposed compounds. The system

ensure the most responsible allocations

quantifies a compound’s potential based on its mechanism of

of microbicide development resources

action, stage of development, potency, safety, prior human

and efficiently reduce time-to-market.

exposure, capacity to formulate and cost of manufacture.

Production Technician Jessica Gonzalez scrapes gel from a Double Planetary PLM-15 Mixer, which is used to blend gel batches for use in
vaginal applicators, at IPM’s CTM Facility in Bethlehem, Pennsylvania, USA. (Andrew Loxley, Felt Photography)
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Moving ahead in the pipeline

Taking combination drugs forward

Several different formulations of IPM’s most advanced candidate,

Developing microbicide candidates that contain drug combina-

dapivirine — which inhibits replication of HIV after the virus enters

tions to prevent HIV on several fronts simultaneously was also a

the cell — continued to move through the pipeline. Studies in 2008

priority for IPM in 2008. To better understand how well combi-

testing the feasibility of a dapivirine vaginal ring as well as gel safety

nations in general may work, IPM intensified studies of dapiv-

and pharmacokinetics, or PK (which reveals how the body process-

irine along with a range of compounds.

es and utilises a compound), all support continued development.
Lead dapivirine gels with demonstrated stability over 12 months are
now being produced for expanded safety and PK studies. In addition, IPM is preparing for preclinical studies of dapivirine film
and a dapivirine vaginal tablet.

A combination including dapivirine and maraviroc is currently
the most advanced in IPM’s pipeline of potential combination
products. Maraviroc is an FDA-approved therapeutic that, like
dapivirine, is stable and affordable. IPM has a robust,
ongoing preclinical programme for the dapivirine

Also progressing in the pipeline is tenofovir,

– maraviroc combination, with safety and PK

another drug that interrupts viral replication

trials scheduled to launch in 2010. IPM is

of HIV once inside the cells and which IPM

studying that combination in sustained-release

acquired from Gilead in 2006. Tenofovir gel

forms such as the vaginal ring and in daily-

was the focus of a PK study and a male toler-

dosage forms, such as the gel or film. IPM
has also initiated work on a combination

ance study — both conducted in part-

maraviroc – tenofovir film.

nership with CONRAD in 2008
— that also supported continued
development.
Other compounds moving
through the pipeline include
an entry blocker that prevents

Andrew Loxley, Felt Photography

HIV from attaching to the host
cell, which IPM obtained from
Bristol-Myers Squibb.

Manufacturing

From the earliest stages of a new compound’s licensing or a new

expanded its own production facility in Pennsylvania, USA. The

formulation’s design, the feasibility of manufacturing helps de-

facility now measures 15,500 square feet, and supports the Good

termine the candidate’s viability. In 2008, IPM began developing

Manufacturing Practice standard for production of rings and gels

a manufacturing strategy for large-scale production of dapivirine

for Phase I/II trials. With its new ring manufacturing capacity,

rings and gels, estimating the potential demand for the products

the facility is moving forward with producing and testing its own

and the requirements of Phase III clinical trials. IPM hopes to

platinum-catalysed dapivirine vaginal rings using a new produc-

build relationships with manufacturers in a variety of countries

tion process that enables large-scale production at the lowest

to produce potential products, and in 2008, IPM renovated and

possible cost.

P R O G R E S S O N T H E PAT H T O H I V P R E V E N T I O N 4
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Fostering global health solutions
Through public-private partnerships

Since 2004, IPM has obtained several non-exclusive

Compound

License

Year

Mechanism of Action

Development Status

royalty-free licenses from pharmaceutical companies to

Dapivirine

Tibotec

2004

NNRTI			

Phase I/II (vaginal gel & ring)

develop, manufacture and distribute ARV compounds as

M167, M872, M882

Merck

2005

CCR5 blockers		

Pre-clinical

microbicides in developing countries. Ensuring access is

BMS793

BMS

2005

gp120 binder		

Early pre-clinical

a cornerstone of IPM’s drug development process. Once

Tenofovir

Gilead

2006

NRTI			

Phase I PK (CONRAD/IPM)

an effective microbicide is developed, these licensing

(IPM & CONRAD)						

Phase IIB (CONRAD/CAPRISA)

						

Phase IIB (MTN, planned)

Maraviroc

Pfizer

2008

CCR5 blocker

Pre-clinical

L’644 peptide

Merck

2008

gp41 binder			

Early pre-clinical

agreements give IPM the full rights to distribute that
product at no or low cost in developing countries.

IPM supports other development
efforts

This year, Osel, Mapp Biopharmaceuticals, Oak Crest Institute of
Science and the Research Triangle Institute received IPM support for studying and developing new microbicide dosage forms.

IPM provides direct funding for the study and development of a
number of encouraging molecules and technologies. For example,

Meanwhile, IPM’s scientific team continued investigation into new
technologies that would improve product compliance.

IPM is working with ImQuest, NIH, CONRAD, the University of
Utah and Particle Sciences, Inc. to implement a joint product development plan for ImQuest’s pyrimidinedione and zinc finger inhibitors. Pyrimidinedione compounds may prevent HIV infection
by inhibiting viral replication and preventing HIV from attaching

IPM also conducted a two-day Toxicology and Formulation Workshop to develop a consensus on procedures for assessing the safety
of candidate microbicides and the process for developing formulations that meet women’s needs.

to target cells. Zinc finger inhibitors inactivate cell-free HIV and
prevent HIV replication in infected cells.
IPM also supported work at the Mintaka Foundation as well as
Drexel University on separate molecules that may
prevent HIV from attaching to healthy cells and infecting them. In addition, IPM is funding work at Gynuity
Health Projects to study whether topical oestrogen improves vaginal health and could make women less vulnerable to HIV. IPM also continues its work with St. George’s
University of London on several projects, including the
screening of molecules submitted by researchers and
organizations from around the world for development as
microbicides.

Mother and daughter outside of their home in Masiphumelele, South Africa.
(Geoff Oliver Bugbee)
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Preparations in 2008 helped
to lay the complex groundwork for
IPM’s microbicide development programme
to move into expanded safety trials in 2009 and efficacy trials that are expected to begin in 2011. Preparing
A recruiter for the Reproductive
Health and HIV Research Unit in
Edendale, South Africa, talks to
community members about
participating in an IPM trial.
(Geoff Oliver Bugbee)

for these trials is a significant undertaking, one that can involve
the creation of new facilities, infrastructure
development, the training of local staff and
leaders, and the engagement of thousands
of individuals.

Richard Lord

The path to clinical trials
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Importance of HIV incidence studies
Preparations for Phase III efficacy trials begin with identifying po-

Building new partnerships, skills
and capacities

tential clinical research centres in areas of the world hardest hit by

Last year, workshops and other

HIV/AIDS, where women face the threat of HIV infection daily.

training helped research centres

Carrying out epidemiological studies of HIV incidence in these
communities helps research centres prepare for microbicide clinical
trials and provides IPM and the countries with invaluable data on
the rate of new HIV infections in specific areas. This also enables
researchers to better measure the effectiveness of potential HIV
prevention products in a future efficacy trial.

11

prepare their budgets for upcoming
safety trials to launch in 2009, and
covered topics in community
engagement, infrastructure
development and staff training.

Community educators for Projet Ubuzima
in Kigali, Rwanda. (Geoff Oliver Bugbee)

The research centre teams were
trained in areas such as clinical safety and data reporting, HIV

If HIV incidence rates are relatively high, a Phase III study may be

testing and counselling, contraceptive and sexually transmitted

conducted in the community. IPM and its local research centre

infection counselling, quality assurance/quality control systems,

partner then work with national and local officials, independent eth-

Good Clinical Practice (GCP), Good Clinical Laboratory Practice

ics committees and community leaders to prepare for the large-scale

(GCLP), laboratory project management, HIV rapid tests, financial

trial to secure the appropriate regulatory and ethics approvals, and

processes and monitoring, and study participant recruitment and

to ensure community support from a wide variety of stakeholders.

retention best practices, among other capacities. In addition, the
September IPM Clinical Affairs Annual Meeting in Cape Town

Research centres prepare for 		
clinical studies

provided more training and a unique opportunity for 200 research
centre attendees from a variety of countries in Africa, Europe and
the United States to exchange ideas and best practices.

Through exploratory visits and incidence studies, IPM has identified approximately 20 clinical research centres that could potentially participate in large-scale trials in Kenya, Malawi, Rwanda,
South Africa, Tanzania, Zambia and Zimbabwe.

2008 studies and trials

IPM and its partners completed studies that measured the incidence of HIV infection in Kigali, Rwanda, in which almost 2,500
women participated. Incidence studies in five locations in South
Africa continue. Another notable 2008 study was a 28-day safety
and pharmacokinetic study of two different dapivirine ring types.
This was the longest clinical trial of a microbicide vaginal ring to
date, and demonstrated that both ring types were safe and welltolerated, and resulted in good distribution of drug in the female
lower genital tract. In addition, a separate safety and acceptability study was conducted in Africa using placebo rings.
A scene from an outreach training session in South Africa. (Geoff Oliver Bugbee)
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Designs for safe trials and reliable data

in communities in which the trials occur. It reflects an idea central
to the fundamental purpose of microbicides and the clinical trial

IPM refined or initiated a number of trial designs to speed time-

process — keeping women healthy and safe.

to-market of a proven-effective microbicide without compromising
safety. Now being further developed is an Adaptive Phase III study
design, which evaluates preliminary effectiveness of a candidate
at early stages of a trial to determine whether the product should

Also created last year was a new IPM clinical safety database that
tracks key safety information. In addition, IPM developed a new
private, interactive website for
research centres that supports

continue to be evaluated.

all aspects of their IPM-sponIPM also updated its Guidelines for Conducting IPM Clinical Trials,
which illustrate IPM’s commitment to meeting international and

sored trials and provides a vehicle for sharing best practices.

local ethical and regulatory standards, and maintaining support

IPM CLINICAL TRIALS WITH ACTIVITY IN 2008

							
TRIAL
DESCRIPTION			

Geoff Oliver Bugbee

IPM 003

Dapivirine vaginal gel safety

COUNTRIES					
Rwanda, South Africa, Tanzania

STATUS IN 2008
Data analysis completed

IPM 004

Dapivirine vaginal gel PK		

South Africa				

Data analysis completed

IPM 007

Seroconverter protocol			

TBD					

In early planning stages

IPM 009

Dapivirine efficacy

TBD

In early planning stages

IPM 010

Dapivirine gel male tolerance		

TBD					

In early planning stages

IPM 011

Placebo vaginal ring safety     
and acceptability			

South Africa, Tanzania,
Kenya					

Ongoing
Site closure

IPM 012

Dapivirine vaginal gel PK		

Belgium					

Clinical trial completed

IPM 013

Dapivirine vaginal ring PK		

Belgium					

In early planning stages

Kenya, Malawi, Rwanda,  South Africa, Tanzania      

In planning stages

IPM 014B Dapivirine vaginal gel safety

Kenya, Malawi, Rwanda,  South Africa, Tanzania        

In planning stages

IPM 015

Dapivirine vaginal ring safety

Kenya, Malawi, Rwanda,  South Africa, Tanzania        

In planning stages

IPM 018

Dapivirine vaginal ring PK/feasibility

Belgium					

Data analysis completed

IPM 020

Dapivirine vaginal gel safety		

United States 				

In planning stages

IPM 021

Dapivirine vaginal ring safety		

Denmark, Germany, Netherlands, United Kingdom

In early planning stages

IPM 022

Smart applicator pilot			

South Africa, USA				

In early planning stages

IPM 014A Dapivirine vaginal gel safety

IPM HIV INCIDENCE STUDIES WITH ACTIVITY IN 2008
STUDY

DESCRIPTION		

COUNTRIES					

STATUS IN 2008

HIVINC
Cross-sectional and prospective cohort
Rwanda					
										

Cross-sectional study completed; prospective 		
cohort study ongoing

IPM 100 Cross-sectional and prospective cohort
South Africa				
										
										

Data analysis initiated (2 centres) ; ongoing, fully
enrolled (2 centres)				
Ongoing, enrolling (1 centre)		

IPM 100.1 Cross-sectional and prospective cohort

In early planning stages

Kenya, South Africa, Zimbabwe			

IPM MARKET RESEARCH STUDIES WITH ACTIVITY IN 2008
STUDY

DESCRIPTION			

COUNTRIES					

STATUS IN 2008

PAS 2

Product acceptability study

Burkina Faso, Mozambique, Tanzania, Zambia

In planning stages

(vaginal tablet, film and soft gel capsule)
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The building blocks of research centre development

Each research centre that agrees to host an IPM study is
different, requiring different types and degrees of support.
In general, site preparation takes the form of community
education and engagement, and improved infrastructure
and training at the research centre itself. Throughout the
process, IPM benefits from the expertise of a variety of
research centres — from learning effective strategies for
engaging local stakeholders to best practices for conducting high-quality clinical trials in a developing country setting.

Community education and engagement
An overarching priority for studies is that people living in
the community fully understand the research activities to be
conducted there. IPM helps research centres cultivate and
develop community frameworks (including a Community
Advisory Board, or CAB) for accomplishing these goals.
These civic structures can remain in place after the trial
ends to help the community achieve future objectives. Members of the community not only learn about the research
study, the clinical trial process and the potential of microbi-

Improved infrastructure
Some facilities may already be in place at a site or they
may need to be created. IPM and its partners work with
communities to purchase or lease and possibly renovate
facilities that exist and then build what is needed. Clinics,
laboratories, pharmacies and offices all take shape where
there were none before, necessary equipment and technology are installed — improvements that may make long-term
contributions to the community.

Training
Site development can support human development.
Research centre leaders, for example, participate in workshops and receive training to make their administration and
outreach more effective. They receive help in customizing
IPM’s community engagement guide to their own research
centres, preparing budgets and writing Standard Operating
Procedures. In addition, local staff are hired and trained in
quality control, quality assurance and specific clinical
procedures. At multiple levels, capability can grow.

cides to prevent HIV, but also apply current best practices
for preventing infection and how to protect their health.

Lititia Pool and Vuyena Patricia Valabile work at
the IPM-sponsored clinic Be Part Yoluntu Centre in
Mbekweni, South Africa.(Geoff Oliver Bugbee)
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For a microbicide product to have an impact on women’s lives, it must
be easily available, acceptable and affordable. That is why wellestablished regulatory pathways are critical to successful product
development, from the earliest stages of preclinical investigation
of a compound. Studies are conducted to determine women’s
product preferences — some women may prefer a gel or
film while still others might prefer to use a longerlasting vaginal ring. Efficient manufacturing capabilities and distribution strategies are created so
products can reach the women who most
need them. The path to impact is
complex, but it leads to real
power over AIDS.

Geoff Oliver Bugbee

Developing a path to access
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Regulatory frameworks and global development
To help prepare for microbicide regulatory approval, IPM and its
partners are helping to support national regulatory and local clinical
capacity in a variety of ways. IPM attended the African Regulatory
Conference in South Africa in February, which was organized by
the Drug Information Association, the Southern African Development Community and the European Federation of Pharmaceutical
Industries and Associations. IPM also convened representatives of
regulatory and ethics committees in Africa in September to discuss
the regulatory pathway for microbicides. In addition, the European
Medicines Agency agreed this past year to review dapivirine
microbicide products under its Article 58, meaning it will give its

Richard Lord

opinion on the products’ use and safety in developing country
settings — an important step towards gaining regulatory approval

Second Annual Microbicide Access Forum in Mexico

for microbicides.
In August, IPM, along with the US Agency for International Devel-

Assessing the impact of product introduction strategies

opment, the European Community, the Population Council and the
World Health Organization, hosted an international gathering that

IPM partnered with the London School of Hygiene and Tropical

focused on facilitating microbicide product access. The attendees

Medicine in a modelling study that compared different microbicide

included donors, microbicide developers, government representa-

product distribution scenarios, gauging their relative cost-effec-

tives, scientists and members of the pharmaceutical industry.

tiveness and potential impact on lowering HIV incidence. The study

The forum gave participants an opportunity to review previous

was conducted in Karnataka, India and Gauteng, South Africa. The

health product launches, and to share new research and avenues

findings help point the way to a product distribution strategy that

for progress.

could lead to significant and cost-effective reductions in HIV infection. IPM published the report in a December policy brief.

From product preference to access
IPM is continuing market research to understand which formulations are most acceptable to women and their partners — from
vaginal tablets and soft gel-capsules to films — and is conducting
an acceptability study of the monthly vaginal ring. To expedite
distribution of any future product, IPM and its partners studied previous commercial product launches in relevant regions,
and began modelling product launch strategies to forecast the
impact and costs of different approaches.

Andrew Loxley, Felt Photography
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IPM mobilises and sustains
support for microbicides to speed
development of products that will give women
prevention options to protect their health and wellbeing. In small meetings and large international events,
IPM focuses attention on the critical importance of microbicide
development to address the global HIV/AIDS epidemic, scientific
advances in the field, and the impact microbicides might one day
make on global health and development. The international community
continues to support microbicide development in very important ways.
Governments, multilateral organizations and foundations are acting on their
recognition that the devastating impact of AIDS requires a coordinated, highGeoff Oliver Bugbee

quality biomedical response.

Partnerships along the path
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Sharing progress and challenges
IPM co-hosted or presented at more than a dozen major events in
2008 to share new findings on microbicide development. Events
included the HIV/AIDS Colloquium on Vaccines and Microbicides Research in South Africa, the UN General Assembly Special
Sessions High-Level Meeting on AIDS, the International AIDS
Conference in Mexico City, the 2008 Global Ministerial Forum on

IPM representatives participate in a panel at the Microbicides 2008 conference in New Delhi.

Research for Health, the Second International Pharmaceutical
Regulatory and Compliance Congress, and Microbicides 2008 in
New Delhi.

the AIDS Vaccine Advocacy Coalition and UNAIDS, IPM briefed
representatives of almost 100 countries. The 2008 UN SecretaryGeneral report, issued in advance of the meeting, discussed the

Growing commitment
Given the substantial and ongoing investment needed to advance
new technologies and conduct clinical trials in developing countries, IPM continually reaches out to sustain the growing momentum towards developing successful microbicide products.
IPM raised awareness about new prevention technologies during
the UN review of the Declaration of Commitments on HIV/AIDS
in New York. Along with the International AIDS Vaccine Initiative,

state of microbicide research.
Throughout the year, IPM briefed key stakeholders in Europe
including policymakers, parliamentarians, scientists and civil
society to raise awareness and build support for microbicides.
In 2008, IPM secured additional funding renewals from Denmark,
France, Germany, Ireland, Spain, Sweden, and Norway and ongoing support from a variety of other donors, including Belgium,
Canada, Netherlands, United Kingdom, United States, the European Commission and a major new commitment from the Bill &
Melinda Gates Foundation. Ongoing support is essential because
funding must be secured before trials can launch — and just a

Professional development:

single efficacy trial alone can cost as much as $120 million.

How to get the message across

How do you report on AIDS? How do you cover ARV-based

workshops to promote literacy on ARV-prevention approaches,

microbicides? At the International AIDS Conference in Mexico,

including microbicides. At IPM’s annual Clinical Affairs meeting in

IPM helped train journalists from around the world in reporting

Cape Town, research centre staff — from Principal Investigators

on AIDS and microbicides. And in September, IPM, along with the

to Community Liaison Officers — learned new ways to communi-

Alliance for Microbicide Development, the AIDS Vaccine Advo-

cate the science of microbicides in the community and to

cacy Coalition and the Global Campaign for Microbicides, hosted

the media.
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FINANCIAL REPORT

ASSETS
Cash and cash equivalents
Investments
Accounts receivables
Prepaid expenses and other assets
Prepaid rent and maintenance, net
Property and equipment, net
Total assets

Dec. 31, 2008

Dec. 31, 2007

$17,183,386
$95,905,340
$1,386,153
$1,238,691
$372,184
$5,040,274
$121,126,028

$15,574,600
$82,519,479
$1,367,232
$1,596,780
$444,731
$2,806,054
$104,308,876

LIABILITIES AND NET ASSETS
Dec. 31, 2008
Liabilities		
Accounts payable and accrued expenses
$7,719,170
Grant advances and deferred revenue
$89,905,178
Total liabilities
$97,624,348
Net Assets		
Unrestricted
$10,102,417
Temporarily restricted
$13,399,263
$23,501,680
Total net assets
Total liabilities and net assets
$121,126,028

Dec. 31, 2007		
$4,149,697
$86,053,553
$90,203,250

$2,565,654
$11,539,972
$14,105,626
$104,308,876

FUNDING CONSIDERATIONS
Conducting clinical trials in developing countries requires sub-

An efficacy trial necessary to support licensure for a single microbi-

stantial financial investment. Between 2002 and the end of 2008,

cide product requires enlisting thousands of women and following

IPM raised $343 million, including $246 million in funds received

them for an extended period so that researchers can compare infec-

and $97 million in commitments for 2009-2013. IPM continues to

tion rates among those who use a candidate microbicide with those

undertake resource development efforts with the understanding

using a placebo. Multiple efficacy trials for microbicide products will

that funding commitments to complete efficacy trials should be in

be required, making IPM’s future financial needs significant. For all

hand before trials can commence, as ethical review boards generally

activities, IPM is committed to serving as a careful steward of public

will not approve a trial without evidence of sufficient funding for

and private donor funds.

completion.

EXPENSES BY DEPARTMENT
Research and Development
Clinical Programmmes
Site Development
Manufacturing
Operations and Administrative
External Relations

All figures shown in US dollars.
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DONORS

Belgian Development Cooperation

Denmark Ministry of Foreign Affairs

Germany Federal Ministry for
Economic Cooperation and Development

Bill & Melinda Gates Foundation

Canadian International Development Agency

European Commission

France Ministry of Foreign Affairs

Irish Aid, Department of Foreign Affairs

Netherlands Ministry of Foreign Affairs

Rockefeller
Foundation
Norwegian Royal Ministry of Foreign Affairs

Rockefeller Foundation

Sweden Ministry for Foreign Affairs

Swedish International Development Cooperation Agency

United Nations Population Fund

United States Agency for International Development

Spain Ministry of Foreign Affairs and Cooperation

United Kingdom Department for International Development

This list includes all donors who have contributed to IPM since its founding in 2002 through 2008.

World Bank
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BOARD of DIRECTORS

Els Borst-Eilers, MD, PhD, Chair
Former Minister of Health, Welfare and
Sport, and former Deputy Prime Minister,
The Netherlands

Alex G. Coutinho, MBChB, MSc,
MPH, Vice Chair
Executive Director, Infectious Diseases
Institute, Makerere University, Uganda

Anjali Nayyar, MA
Country Programme Leader for India,
PATH, India

Albert Profy, PhD

Eunice Brookman-Amissah, MBChB

Rajat Kumar Gupta, MBA

Vice President for Africa, Ipas, Kenya

Senior Partner Worldwide, McKinsey &
Company, United States

Vice President, Preclinical and Pharmaceutical Sciences, Endo Pharmaceuticals,
United States

Seth L. Harrison, MD, MBA

Zeda F. Rosenberg, ScD

Managing General Partner, Apple Tree
Partners, United States

Chief Executive Officer, IPM, United States

Eveline Herfkens, MA

Former Director General, AIDES, France

UN Executive Coordinator for the
Millennium Development Goals
Campaign, United States

Anita Sandström, Dr Med Sc

Peter Corr, PhD
General Partner, Celtic Therapeutics
Management, United States

David Kessler, JD, MD
Professor of Pediatrics, University of
California, San Francisco School of Medicine, United States

Totsie Memela-Khambula, MPA

Hélène Rossert-Blavier, MD, MPH

Executive Director, Southern African AIDS
Trust, South Africa

Anandi Yuvaraj, MSc, MPhil, PGDGC
Regional Coordinator, International Community of Women Living with HIV/AIDS,
Thailand

Managing Director, Post Bank, South Africa
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SCIENTIFIC ADVISORY BOARD, EXECUTIVE COMMITTEE

Robin Shattock, PhD, Chair

Sharon Hillier, PhD

Martin Springer, PhD

St. George’s University of London,
United Kingdom

University of Pittsburgh, United States

Merck & Co. (retired), United States

Ruth Merkatz, PhD

Jens van Roey, PhD

Richard Bax, PhD

Tibotec, Belgium

ViroPharma, Europe, United Kingdom

Population Council Center for Biomedical
Research, United States

Benjamin Cheng, MSc

Thomas Moench, MD

PATH, United States

ReProtect, United States

Gustavo F. Doncel, MD, PhD

Lynn Paxton, MD, MPH

CONRAD of the Eastern Virginia Medical
School, United States

U.S. Centers for Disease Control and Prevention, United States
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SENIOR MANAGEMENT TEAM

Geoff Oliver Bugbee

Zeda F. Rosenberg, ScD

Esther Benjamin, MA, MS

Chief Executive Officer

Executive Director, Resource
Development

Janelle Bryant, MBA
Chief Financial Officer

Karen McCord

Annalene Nel, MD, PhD

Executive Director, Operations 		
and Planning

Chief Medical Officer

Pamela Norick, MA
Chief of External Relations

Thomas Mertenskoetter, MD
Executive Director, External Relations,
Europe

Joseph Romano, MS, PhD
Chief of Product Development
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2008 INTERNATIONAL PARTNERS

Advanced Biosciences Laboratory,

USA

Adhesives Research (ARx), USA

Equilibres & Populations, France
European Microbicide Project,

United Kingdom

African Microbicides Advocacy Group,

Family Health International, USA

Afrimesh Research and Care (PHIVA),

German Foundation for World
Population (DSW), Germany

Ghana

South Africa

AIDES, France

Gilead Sciences, USA
Global Campaign for Microbicides,

AIDS Fondet, Denmark

USA

AIDS Fonds, The Netherlands

Global Coalition on Women and AIDS,

AIDS Vaccine Advocacy Coalition,

USA

Ajinomoto OmniChem, Belgium
Albert Einstein College of Medicine
(AECOM), USA
Alliance for Microbicide Development,

USA

Analytical Solutions, USA
Azopharma, USA
Be Part Yoluntu Centre,

South Africa

Bristol-Myers Squibb, USA
Catalent Pharma Solutions, USA
CBR Institute for Biomedical
Research, USA
Clinton Global Initiative, USA
Colloid Consultants Ltd, USA
CONRAD, USA
Cornell University, USA
Desmond Tutu HIV Foundation,

South Africa

Dinox, The Netherlands
Diteba Research Laboratories, USA
Dow Corning Corporation, USA
Drexel University Medical School, USA

Switzerland

Grupo de Trabajo sobre Tradatimento
de VIH, Spain

Richard Lord

Madibeng Centre for Research (MCR),

South Africa

Magee Women’s Research Institute,
University of Pittsburgh School of
Medicine, USA
McGill University, Canada
Medical Research Council,

South Africa

Merck & Co., USA
Microbicide Development Programme,

United Kingdom

Microbicide Trials Network, USA
Mount Sinai School of Medicine, USA

Gynuity Health Projects, USA

MR Solutions, USA

Health and Development Africa,

National AIDS Trust, United Kingdom

South Africa

HIV Vaccine Trials Unit, Fred Hutchinson Cancer Research Center, USA

National Institute for Research in
Reproductive Health, India

Imquest Biosciences, USA

National Institute of Allergy and Infectious Diseases, USA

Institute of Tropical Medicine, Belgium

Noaks Ark Foundation, Sweden

Interagency Coalition on AIDS and
Development, Canada

North American Science Associates
Inc. (NAMSA), USA

International Centre for Reproductive
Health, Kenya

Northwestern University, USA

J-Star Research, USA
Johnson & Johnson (Tibotec Pharmaceuticals), Belgium
Kenya Medical Research Institute,

Kenya

KBI BioPharma Inc, USA
Kilimanjaro Christian Medical Centre,

Tanzania

Locus Pharmaceuticals, USA
London School of Hygiene and
Tropical Medicine, United Kingdom
Malawi College of Medicine/Johns
Hopkins Research Project, Malawi

Norwegian Association for Sexual
and Reproductive Health and Rights
(NSRR), Norway
Novavax, USA
Nusil Technology LLC, USA
Oak Crest Institute of Science, USA
Osel, USA
Paragon Sciences, USA
Particle Sciences, USA
Pfizer, USA
PharmaForm LLC, USA
Planet Health, Spain
Population Council, USA
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Princeton API, USA

Schering-Plough, USA

PRA International, The Netherlands

ScinoPharm, Taiwan

Prevention of HIV/AIDS Project
(PHIVA), South Africa

Sensoa, Belgium

Project WISH, University of Illinois at
Chicago (UIC), USA

SSCI Inc, USA

Projet Ubuzima, Rwanda
Qhakaza Mbokodo, South Africa
QuartRX Biomedical Corporation, USA
Queen’s University Belfast, United

Kingdom

Regulatory Compliance Initiatives,

USA

Reproductive Health and HIV
Research Unit (RHRU), South Africa
Reprotect, USA
Research IQ, South Africa
Research Triangle Institute, USA
Richmond Pharmacology Ltd., St.
George’s University of London,

United Kingdom
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SGS Life Science Services, Belgium
Statistics Collaborative, USA
St. George’s University of London,

United Kingdom

St. Stephen’s Centre, United Kingdom
SNBL Clinical Pharmacology Center,

USA

Steadman Group, Kenya
Stratos Product Development, USA

University of California at Los
Angeles, USA
University of Cape Town, South Africa
University of Copenhagen,
Copenhagen HIV Programme (CHIP),

Denmark

University of Ghent, Belgium
University Hospital-Eppendorf,

Germany

University of Pennsylvania, USA
University of Utah, USA
University of the Witwatersrand,

South Africa

University of Zimbabwe, Zimbabwe

UNAIDS, Global Coalition on Women
and AIDS, Switzerland

Voxiva, USA

University of Alabama at Birmingham
(UAB), USA

World Health Organization, Switzerland

University of Auckland, New Zealand

Warner Chilcott, United Kingdom
Xigo Nanotools, USA

23

4

24

SELECTED SCIENTIFIC PUBLICATIONS and PRESENTATIONS
SUPPORTED BY IPM IN 2008

Bryla P, Romano J, Nuttall J, Race S,
Fairhurst D, Gwozdz G, Thakker K.
In-Vitro Release Rate Testing (IVRT) as a
Performance Test for Dapivirine (TMC –
120) Vaginal Gels. Poster presentation at
Microbicides 2008, 24-27 February,
New Delhi.

Cates W, Rosenberg Z. Vaginal
microbicides: What does the future hold?
Contemporary OB/GYN Supplement,
April 15, 2008.

Douville K, West S, Mitchnick L,
Woodsong C, Romano J, Mitchnick M,
Rosenberg Z. A Vaginal Gel Product
Attribute Study: Market Research in the
Developing World to Support
Microbicide Development. Poster
presentation at Microbicides 2008,
24-27 February, New Delhi.

Garg AB. Combination Microbicide
Products: An Overview. Oral presentation
at Microbicides 2008, 24-27 February,
New Delhi.

Garg AB, Carter J, Rubinstein S,
Douville K. 2007 Worldwide
Manufacturing Capabilities Survey.
Poster presentation at Microbicides 2008,
24-27 February, New Delhi.

Gupta KM, Pearce SM, Poursaid AE, Aliyar
HA, Tresco PA, Mitchnick MA, Kiser PF.
Polyurethane intravaginal ring for
controlled delivery of dapivirine,
a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci.
2008;97(10):4228-39.

Nel A, Coplan P, Smythe S, Douville K,
Romano J, Mitchnick M. Pharmacokinetic
Assessment of an Anti-HIV Dapivirine
Vaginal Microbicide Gel (Gel – 002).
Oral presentation at Microbicides 2008,
24-27 February, New Delhi.

Nel A, Smythe S, Young K, Malcolm K,
Rosenberg Z, Romano J. Safety and
Pharmacokinetic Assessment of 28 Day
Anti-HIV Dapivirine Intravaginal
Microbicide Rings. Poster presentation
at 15th Conference on Retroviruses and
Opportunistic Infections, 3-6 February,
Boston.

Nuttall J, Plummer S, Fletcher P, Shattock
R, Romano J. The Use of Oligonucleotide
Based Microarray Data from Human
Cervical and Vaginal Epithelial Cell Lines
as a Model for Characterizing the
Potential Local Toxicity of Candidate
Microbicides. Oral presentation at
Microbicides 2008, 24-27 February,
New Delhi.

Nuttall JP, Thake DC, Lewis MG, Ferkany
JW, Romano JW, Mitchnick MA. Concentrations of dapivirine in the rhesus
macaque and rabbit following once
daily intravaginal administration of a
gel formulation of [14C]dapivirine for
7 days. Antimicrob Agents Chemother.
2008;52(3):909-14.

Romano J, Malcolm RK, Garg S, Rohan
LC, Kaptur PE. Microbicide delivery:
formulation technologies and strategies.
Curr Opin HIV AIDS. 2008;3:558-66.

Smythe S, Ferreira MM, Kapiga S,
Masenga G, Moyes J, Rees H, van de
Wijgert J, Von Mollendorf C,
Vyankandondera J, Nel A. Clinical Safety
and Tolerability Assessment of an
Anti-HIV Dapivirine Vaginal Microbicide
Gel (Gel – 002). Oral presentation at
Microbicides 2008, 24-27 February,
New Delhi.

Tawfik Y. Panel on Planning for
Introduction and Access. Oral
presentation at Microbicides 2008,
24-27 February, New Delhi.

Tawfik Y. Microbicide Access Forum 2007
– Nairobi Summary Report. Oral presentation at Microbicides 2008, 24-27 February, New Delhi.

Tawfik Y, Raghavendran V, Dickson K,
Walker S. Proceedings from the
Microbicide Access Forum 2007. Poster
presentation at Microbicides 2008, 24-27
February, New Delhi.

Rosenberg Z. Alternative Trial Designs.
Oral presentation at Microbicides 2008,
24-27 February, New Delhi.
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www.ipm-microbicides.com
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